Mirthe H. W. van Veghel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mirthe H. W. van Veghel has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Gerjon Hannink
Department of Medical Imaging, Radboudumc, Nijmegen, The Netherlands
9 shared publications - Berend Willem Schreurs
Department of Orthopaedics, Radboud University Medical Center, Nijmegen, the Netherlands
8 shared publications - Liza N. van Steenbergen
Dutch Arthroplasty Register (LROI), ‘s-Hertogenbosch, The Netherlands
7 shared publications - Peter L. Lewis
Australian Orthopaedic Association National Joint Replacement Registry
2 shared publications Anneke Spekenbrink-Spooren
Dutch Arthroplasty Register (Landelijke Registratie Orthopedische Interventies), 's-Hertogenbosch, The Netherlands
1 shared publicationBart C H Van der Wal
Department of Orthopedic Surgery, University Medical Center Utrecht, Utrecht, The Netherlands
1 shared publication
Latest Publications
- Open Access
- 10 March 2026
- Published by Medical Journals Sweden AB in Acta Orthopaedica
- Vol. 97, 177–184
Assessing the value for money of a registry: an exploratory analysis of the Dutch Arthroplasty Register
Background and purpose: It is unclear whether arthroplasty registries provide value for money. We aimed to provide insight into this value for money by relating the costs of the Dutch Arthroplasty Register (LROI) to potential benefits from preventing revisions.Methods: We included all primary total hip (n = 276,252) and knee (n = 217,901) arthroplasties (THA/TKA), and all first revisions of these THAs (n = 8,604) and TKAs (n = 8,745) from the LROI between 2014 and 2022. Threshold analyses estimated at which number of prevented revisions the benefits (i.e., savings and increased quality of life) outweighed the LROI costs. Scenario analyses explored whether the required revision reductions were feasible, including the minimum revision reduction required per hospital, revision reduction at outlier hospitals only, and the potential impact of temporal changes in national 1-year revision rates.Results: The LROI costs were €5,697,120 for THA registration and €4,532,920 for TKA registration between 2014 and 2022. Preventing 119 to 145 THA revisions and 106 to 134 TKA revisions would be required in the current patient population over 30 years for the benefits to outweigh these LROI costs between 2014 and 2022, depending on revision costs. Each Dutch hospital should prevent 1.2 to 1.5 THA revisions and 1.1 to 1.3 TKA revisions to achieve the required revision reduction. Moreover, 306 THA revisions and 140 TKA revisions could be prevented if outlier hospitals improved their 1-year overall revision rate to the upper 99% control limit. Compared with the calendar years showing the highest revision rates, applying 2022 1-year revision rates to 2023 procedure volumes resulted in reductions of 1.5% for THAs and 0.3% for TKAs.Conclusion: Preventing approximately 1–2 revisions per hospital over 30 years would offset the LROI’s registration costs. Although causality cannot be established, these findings suggest that national arthroplasty registries may provide good value for money when actively used to reduce revision rates.
- 10 March 2026
- Published by Medical Journals Sweden AB in Acta Orthopaedica
- Vol. 97, 177–184
Open AccessAssessing the value for money of a registry: an exploratory analysis of the Dutch Arthroplasty Register
Background and purpose: It is unclear whether arthroplasty registries provide value for money. We aimed to provide insight into this value for money by relating the costs of the Dutch Arthroplasty Register (LROI) to potential benefits from preventing revisions.Methods: We included all primary total hip (n = 276,252) and knee (n = 217,901) arthroplasties (THA/TKA), and all first revisions of these THAs (n = 8,604) and TKAs (n = 8,745) from the LROI between 2014 and 2022. Threshold analyses estimated at which number of prevented revisions the benefits (i.e., savings and increased quality of life) outweighed the LROI costs. Scenario analyses explored whether the required revision reductions were feasible, including the minimum revision reduction required per hospital, revision reduction at outlier hospitals only, and the potential impact of temporal changes in national 1-year revision rates.Results: The LROI costs were €5,697,120 for THA registration and €4,532,920 for TKA registration between 2014 and 2022. Preventing 119 to 145 THA revisions and 106 to 134 TKA revisions would be required in the current patient population over 30 years for the benefits to outweigh these LROI costs between 2014 and 2022, depending on revision costs. Each Dutch hospital should prevent 1.2 to 1.5 THA revisions and 1.1 to 1.3 TKA revisions to achieve the required revision reduction. Moreover, 306 THA revisions and 140 TKA revisions could be prevented if outlier hospitals improved their 1-year overall revision rate to the upper 99% control limit. Compared with the calendar years showing the highest revision rates, applying 2022 1-year revision rates to 2023 procedure volumes resulted in reductions of 1.5% for THAs and 0.3% for TKAs.Conclusion: Preventing approximately 1–2 revisions per hospital over 30 years would offset the LROI’s registration costs. Although causality cannot be established, these findings suggest that national arthroplasty registries may provide good value for money when actively used to reduce revision rates.
- Open Access
- 4 March 2025
- Published by Medical Journals Sweden AB in Acta Orthopaedica
- Vol. 96, 226–234
Identifying recovery trajectories following primary total shoulder arthroplasty: a cohort study of 3,358 patients from the Dutch Arthroplasty Register
Background and purpose: Some patients do not improve after total shoulder arthroplasty (TSA), indicating different recovery trajectories. We aimed to identify recovery trajectories after TSA based on the Oxford Shoulder Score (OSS). Second, we investigated whether recovery trajectories were associated with patient or procedure characteristics.Methods: We included primary anatomical and reversed TSAs (ATSAs/RTSAs) for osteoarthritis (OA) or cuff arthropathy/rupture with preoperative, 3-month, and/or 12-month postoperative OSS, registered between 2016 and 2022 in the Dutch Arthroplasty Register (n = 3,358). We used latent class growth modeling (LCGM) to identify recovery patterns, and multinomial logistic regression analyses to investigate associations between potential risk factors and class membership (odds ratio [OR], 95% confidence interval [CI]).Results: We identified 3 recovery patterns: “Fast responders” (59%), “Steady responders” (27%), and “Poor responders” (14%). Factors associated with “Steady responders” vs “Fast responders” were female vs male sex (OR 2.0, CI 1.5–2.7), ASA III–IV vs ASA I (OR 1.9, CI 1.2–3.1), Walch A1 vs B2 (OR 1.6, CI 1.1–2.5), and most vs medium socioeconomic deprivation (OR 1.4, CI 1.1–1.9). Factors associated with “Poor responders” vs “Fast responders” were ASA II vs ASA I (OR 2.0, CI 1.1–3.6), ASA III–IV vs ASA I (OR 3.0, CI 1.6–5.5), Walch A1 vs B2 (OR 2.1, CI 1.3–3.3), previous shoulder surgeries (OR 1.8, CI 1.3–2.4), most vs medium socioeconomic deprivation (OR 1.5, CI 1.2–2.0), RTSA for OA vs ATSA for OA (OR 1.8, CI 1.2–2.7), and RTSA for cuff arthropathy or rupture vs ATSA for OA (OR 2.3, CI 1.5–3.4).Conclusion: 3 recovery trajectories were identified following TSA, which we labelled as “Fast responders,” “Steady responders,” and “Poor responders.” “Steady responders” and “Poor responders” were more likely to have higher ASA scores, a Walch A1 vs B2 classification, and greater vs medium socioeconomic deprivation than “Fast responders.” Moreover, “Steady responders” were more likely to be female, while “Poor responders” were more likely to have previous shoulder surgeries and RTSA for OA or for cuff arthropathy or rupture than “Fast responders.”
- 4 March 2025
- Published by Medical Journals Sweden AB in Acta Orthopaedica
- Vol. 96, 226–234
Open AccessIdentifying recovery trajectories following primary total shoulder arthroplasty: a cohort study of 3,358 patients from the Dutch Arthroplasty Register
Background and purpose: Some patients do not improve after total shoulder arthroplasty (TSA), indicating different recovery trajectories. We aimed to identify recovery trajectories after TSA based on the Oxford Shoulder Score (OSS). Second, we investigated whether recovery trajectories were associated with patient or procedure characteristics.Methods: We included primary anatomical and reversed TSAs (ATSAs/RTSAs) for osteoarthritis (OA) or cuff arthropathy/rupture with preoperative, 3-month, and/or 12-month postoperative OSS, registered between 2016 and 2022 in the Dutch Arthroplasty Register (n = 3,358). We used latent class growth modeling (LCGM) to identify recovery patterns, and multinomial logistic regression analyses to investigate associations between potential risk factors and class membership (odds ratio [OR], 95% confidence interval [CI]).Results: We identified 3 recovery patterns: “Fast responders” (59%), “Steady responders” (27%), and “Poor responders” (14%). Factors associated with “Steady responders” vs “Fast responders” were female vs male sex (OR 2.0, CI 1.5–2.7), ASA III–IV vs ASA I (OR 1.9, CI 1.2–3.1), Walch A1 vs B2 (OR 1.6, CI 1.1–2.5), and most vs medium socioeconomic deprivation (OR 1.4, CI 1.1–1.9). Factors associated with “Poor responders” vs “Fast responders” were ASA II vs ASA I (OR 2.0, CI 1.1–3.6), ASA III–IV vs ASA I (OR 3.0, CI 1.6–5.5), Walch A1 vs B2 (OR 2.1, CI 1.3–3.3), previous shoulder surgeries (OR 1.8, CI 1.3–2.4), most vs medium socioeconomic deprivation (OR 1.5, CI 1.2–2.0), RTSA for OA vs ATSA for OA (OR 1.8, CI 1.2–2.7), and RTSA for cuff arthropathy or rupture vs ATSA for OA (OR 2.3, CI 1.5–3.4).Conclusion: 3 recovery trajectories were identified following TSA, which we labelled as “Fast responders,” “Steady responders,” and “Poor responders.” “Steady responders” and “Poor responders” were more likely to have higher ASA scores, a Walch A1 vs B2 classification, and greater vs medium socioeconomic deprivation than “Fast responders.” Moreover, “Steady responders” were more likely to be female, while “Poor responders” were more likely to have previous shoulder surgeries and RTSA for OA or for cuff arthropathy or rupture than “Fast responders.”
- Open Access
- 13 January 2025
- Published by British Editorial Society of Bone & Joint Surgery in Bone & Joint Open
- Vol. 6 (1) , 74-81
How many people in the Netherlands live with a hip, knee, or shoulder replacement?
Aims: We estimated the prevalence of people living with at least one hip, knee, or shoulder arthroplasty in the Netherlands.Methods: We included the first hip (n = 416,333), knee (n = 314,569), or shoulder (n = 23,751) arthroplasty of each patient aged ≥ 40 years between 2007 and 2022 (hip/knee) or 2014 and 2022 (shoulder) from the Dutch Arthroplasty Register (LROI). Data on the size of the Dutch population were obtained from Statistics Netherlands. Annual incidences and deaths from hip and knee arthroplasty since 2010, and shoulder arthroplasty since 2015, were observed from the LROI. Annual incidences and deaths before those years were estimated using Poisson regression analyses and parametric survival models based on a Gompertz distribution. Non-parametric percentile bootstrapping with resampling was used to estimate 95% CIs.Results: Annual incidences per 100,000 Dutch inhabitants aged ≥ 40 years increased for hip arthroplasties from 221 (95% CI 214 to 229) in 1990 to 360 in 2022, for knee arthroplasties from 181 (95% CI 174 to 188) to 272, and for shoulder arthroplasties from 11 (95% CI 8.0 to 16) to 34. In 2022, 791,000 (95% CI 787,000 to 794,000) people in the Netherlands were living with at least one joint replacement, representing 8.4% (95% CI 8.4 to 8.5) of the Dutch population aged ≥ 40 years. For hip, knee, and shoulder arthroplasties, these were 436,000 (95% CI 433,000 to 438,000), 383,000 (95% CI 380,000 to 386,000), and 34,000 (95% CI 33,000 to 36,000) people, corresponding to 4.7% (95% CI 4.6 to 4.7), 4.1% (95% CI 4.1 to 4.1), and 0.4% (95% CI 0.3 to 0.4) of the Dutch population, respectively. The most common age group living with at least one joint replacement was the ≥ 80-year age group, representing 38% (95% CI 37 to 38) of the Dutch population aged ≥ 80 years.Conclusion: Approximately 800,000 people in the Netherlands were living with at least one hip, knee, or shoulder replacement in 2022, representing one in 12 Dutch inhabitants aged ≥ 40 years.Cite this article: Bone Jt Open 2025;6(1):74–81.
- 13 January 2025
- Published by British Editorial Society of Bone & Joint Surgery in Bone & Joint Open
- Vol. 6 (1) , 74-81
Open AccessHow many people in the Netherlands live with a hip, knee, or shoulder replacement?
Aims: We estimated the prevalence of people living with at least one hip, knee, or shoulder arthroplasty in the Netherlands.Methods: We included the first hip (n = 416,333), knee (n = 314,569), or shoulder (n = 23,751) arthroplasty of each patient aged ≥ 40 years between 2007 and 2022 (hip/knee) or 2014 and 2022 (shoulder) from the Dutch Arthroplasty Register (LROI). Data on the size of the Dutch population were obtained from Statistics Netherlands. Annual incidences and deaths from hip and knee arthroplasty since 2010, and shoulder arthroplasty since 2015, were observed from the LROI. Annual incidences and deaths before those years were estimated using Poisson regression analyses and parametric survival models based on a Gompertz distribution. Non-parametric percentile bootstrapping with resampling was used to estimate 95% CIs.Results: Annual incidences per 100,000 Dutch inhabitants aged ≥ 40 years increased for hip arthroplasties from 221 (95% CI 214 to 229) in 1990 to 360 in 2022, for knee arthroplasties from 181 (95% CI 174 to 188) to 272, and for shoulder arthroplasties from 11 (95% CI 8.0 to 16) to 34. In 2022, 791,000 (95% CI 787,000 to 794,000) people in the Netherlands were living with at least one joint replacement, representing 8.4% (95% CI 8.4 to 8.5) of the Dutch population aged ≥ 40 years. For hip, knee, and shoulder arthroplasties, these were 436,000 (95% CI 433,000 to 438,000), 383,000 (95% CI 380,000 to 386,000), and 34,000 (95% CI 33,000 to 36,000) people, corresponding to 4.7% (95% CI 4.6 to 4.7), 4.1% (95% CI 4.1 to 4.1), and 0.4% (95% CI 0.3 to 0.4) of the Dutch population, respectively. The most common age group living with at least one joint replacement was the ≥ 80-year age group, representing 38% (95% CI 37 to 38) of the Dutch population aged ≥ 80 years.Conclusion: Approximately 800,000 people in the Netherlands were living with at least one hip, knee, or shoulder replacement in 2022, representing one in 12 Dutch inhabitants aged ≥ 40 years.Cite this article: Bone Jt Open 2025;6(1):74–81.
- 30 December 2024
- Published by Wolters Kluwer Health in Clinical Orthopaedics and Related Research
- Vol. 483 (6) , 1010-1019
Do Cumulative Revision Rate and First-time Re-revision Rate Vary Between Short and Standard Femoral Stem Lengths? A Multinational Registry Study
Background: Advocates of short-stem THA suggest that these devices preserve proximal femoral bone for future revisions. This contention is as yet unsupported by robust evidence, and ultimately, it will be irrelevant if short-stem THA increases the overall risk of premature revision. To our knowledge, large, registry-based efforts have yet to explore the types of stems used in first-time stem revision as well as the survivorship of short versus standard-length femoral stems in THA. Questions/purposes: (1) Which stems are used in the first stem revision of primary short-stem and standard-stem THAs? (2) What is the overall cumulative revision rate (CRR) of primary short-stem THAs compared with primary standard-stem THAs? (3) What is the overall cumulative re-revision rate of primary short-stem THAs compared with primary standard-stem THAs? Methods: Patients with short-stem THAs, defined as a short stem with mainly metaphyseal fixation, registered in the Australian Orthopaedic Association National Joint Replacement Register (AOANJRR), the Dutch Arthroplasty Register (Landelijke Registratie Orthopedische Interventies [LROI]), or the Swedish Arthroplasty Register (SAR) between January 2007 and December 2022 were included (n = 15,771), as well as a propensity score–matched cohort (1:2) with standard-stem THAs, defined as a stem with a standard length (n = 31,542). Groups were matched on sex, age, year of procedure, diagnosis, bearing material, and surgical approach. After matching, the groups did not differ in terms of age (mean ± SD 63 ± 11 versus 64 ± 11 years), sex (48% [7546 of 15,771] male versus 48% [15,093 of 31,542] male), and diagnosis (93% [14,655 of 15,771] osteoarthritis [OA] versus 94% [29,585 of 31,542] OA). We used those three registries because all are high-quality national arthroplasty registries with high levels of completeness. Also, the AOANJRR is the only registry globally that reports on short-stem THA as its own entity. The type of stem used in revision surgery was classified as standard stem (< 160 mm) or long stem (≥ 160 mm). Overall CRR of primary THAs at 12 years of follow-up and overall CRR of all first-time revisions at 5 years were calculated using Kaplan-Meier survival analyses. Any type of revision was used as endpoint. Results: In first-time stem revisions of the short-stem THAs, a standard stem was used more often (58% [116 of 201]) than in the revision of standard-stem THAs (46% [149 of 322]; p = 0.01). The 12-year overall CRRs between primary short-stem and standard-stem THAs did not differ (4.7% [95% confidence interval (CI) 4.0% to 5.5%] versus 5.1% [95% CI 4.5% to 5.7%], respectively; p = 0.20). The overall CRR for a second revision at 5 years also did not differ when primary short-stem THAs were compared with standard-stem THAs (20.9% [95% CI 16.8% to 25.8%]) versus 20.4% [95% CI 17.3% to 23.9%]; p = 0.80). Conclusion: In light of these findings, there may be a perceived benefit of using short stems in primary THA if a revision is later required, as the short stems included in this study were to a higher degree revised using a standard (more bone-sparing) stem. Further, the first and second overall CRR of the studied short-stem THAs did not differ from that of standard-stem THAs, also supporting use of short-stem THA. Further research, preferably multinational registry-based studies, should be performed to confirm our findings. Level of Evidence: Level III, therapeutic study.
- 30 December 2024
- Published by Wolters Kluwer Health in Clinical Orthopaedics and Related Research
- Vol. 483 (6) , 1010-1019
Do Cumulative Revision Rate and First-time Re-revision Rate Vary Between Short and Standard Femoral Stem Lengths? A Multinational Registry Study
Background: Advocates of short-stem THA suggest that these devices preserve proximal femoral bone for future revisions. This contention is as yet unsupported by robust evidence, and ultimately, it will be irrelevant if short-stem THA increases the overall risk of premature revision. To our knowledge, large, registry-based efforts have yet to explore the types of stems used in first-time stem revision as well as the survivorship of short versus standard-length femoral stems in THA. Questions/purposes: (1) Which stems are used in the first stem revision of primary short-stem and standard-stem THAs? (2) What is the overall cumulative revision rate (CRR) of primary short-stem THAs compared with primary standard-stem THAs? (3) What is the overall cumulative re-revision rate of primary short-stem THAs compared with primary standard-stem THAs? Methods: Patients with short-stem THAs, defined as a short stem with mainly metaphyseal fixation, registered in the Australian Orthopaedic Association National Joint Replacement Register (AOANJRR), the Dutch Arthroplasty Register (Landelijke Registratie Orthopedische Interventies [LROI]), or the Swedish Arthroplasty Register (SAR) between January 2007 and December 2022 were included (n = 15,771), as well as a propensity score–matched cohort (1:2) with standard-stem THAs, defined as a stem with a standard length (n = 31,542). Groups were matched on sex, age, year of procedure, diagnosis, bearing material, and surgical approach. After matching, the groups did not differ in terms of age (mean ± SD 63 ± 11 versus 64 ± 11 years), sex (48% [7546 of 15,771] male versus 48% [15,093 of 31,542] male), and diagnosis (93% [14,655 of 15,771] osteoarthritis [OA] versus 94% [29,585 of 31,542] OA). We used those three registries because all are high-quality national arthroplasty registries with high levels of completeness. Also, the AOANJRR is the only registry globally that reports on short-stem THA as its own entity. The type of stem used in revision surgery was classified as standard stem (< 160 mm) or long stem (≥ 160 mm). Overall CRR of primary THAs at 12 years of follow-up and overall CRR of all first-time revisions at 5 years were calculated using Kaplan-Meier survival analyses. Any type of revision was used as endpoint. Results: In first-time stem revisions of the short-stem THAs, a standard stem was used more often (58% [116 of 201]) than in the revision of standard-stem THAs (46% [149 of 322]; p = 0.01). The 12-year overall CRRs between primary short-stem and standard-stem THAs did not differ (4.7% [95% confidence interval (CI) 4.0% to 5.5%] versus 5.1% [95% CI 4.5% to 5.7%], respectively; p = 0.20). The overall CRR for a second revision at 5 years also did not differ when primary short-stem THAs were compared with standard-stem THAs (20.9% [95% CI 16.8% to 25.8%]) versus 20.4% [95% CI 17.3% to 23.9%]; p = 0.80). Conclusion: In light of these findings, there may be a perceived benefit of using short stems in primary THA if a revision is later required, as the short stems included in this study were to a higher degree revised using a standard (more bone-sparing) stem. Further, the first and second overall CRR of the studied short-stem THAs did not differ from that of standard-stem THAs, also supporting use of short-stem THA. Further research, preferably multinational registry-based studies, should be performed to confirm our findings. Level of Evidence: Level III, therapeutic study.
- Open Access
- 13 September 2024
- Published by Medical Journals Sweden AB in Acta Orthopaedica
- Vol. 95, 545–552
Association of osteotomy, age, and component fixation with the outcomes of total hip arthroplasty in patients with hip dysplasia: a Dutch population-based registry study
Background and purpose: Hip dysplasia can present challenges for total hip arthroplasty (THA) due to anatomic abnormalities. We aimed to assess the association of age, sex, osteotomies prior to THA, and fixation method on 5- and 10-year revision-free implant survival and patient-reported outcome measures (PROMs) of THAs in patients with hip dysplasia.Methods: Using Dutch Arthroplasty Register data, we studied hip dysplasia patients receiving primary THAs in 2007–2021 (n = 7,465). THAs were categorized by age, pelvic osteotomy prior to THA (yes/no), and fixation (cemented, uncemented, hybrid, reverse hybrid). Kaplan–Meier and multivariable Cox models were used to determine 5- and 10-year revision-free implant survival and adjusted hazard ratios including 95% confidence intervals (CIs). Reasons for revision and PROMs were compared within the categories.Results: We found a 10-year revision-free implant survival of 94.9% (CI 94.3–95.5). Patients younger than 50 years had a 10-year implant survival of 93.3% (CI 91.9–94.7), Patients with prior pelvic osteotomy had a 10-year implant survival of 92.0% (CI 89.8–94.2). Fixation method and sex were not associated with implant survival. Patients with a prior pelvic osteotomy had more revisions due to cup loosening and reported lower PROM scores than patients without earlier osteotomy.Conclusion: 5- and 10-year revision-free implant survival rates of THA for hip dysplasia are 96.4% and 94.9%. Age and prior osteotomies were associated with decreased implant survival rates in patients with hip dysplasia, while fixation method was not. Prior osteotomies were also associated with reduced PROM scores.
- 13 September 2024
- Published by Medical Journals Sweden AB in Acta Orthopaedica
- Vol. 95, 545–552
Open AccessAssociation of osteotomy, age, and component fixation with the outcomes of total hip arthroplasty in patients with hip dysplasia: a Dutch population-based registry study
Background and purpose: Hip dysplasia can present challenges for total hip arthroplasty (THA) due to anatomic abnormalities. We aimed to assess the association of age, sex, osteotomies prior to THA, and fixation method on 5- and 10-year revision-free implant survival and patient-reported outcome measures (PROMs) of THAs in patients with hip dysplasia.Methods: Using Dutch Arthroplasty Register data, we studied hip dysplasia patients receiving primary THAs in 2007–2021 (n = 7,465). THAs were categorized by age, pelvic osteotomy prior to THA (yes/no), and fixation (cemented, uncemented, hybrid, reverse hybrid). Kaplan–Meier and multivariable Cox models were used to determine 5- and 10-year revision-free implant survival and adjusted hazard ratios including 95% confidence intervals (CIs). Reasons for revision and PROMs were compared within the categories.Results: We found a 10-year revision-free implant survival of 94.9% (CI 94.3–95.5). Patients younger than 50 years had a 10-year implant survival of 93.3% (CI 91.9–94.7), Patients with prior pelvic osteotomy had a 10-year implant survival of 92.0% (CI 89.8–94.2). Fixation method and sex were not associated with implant survival. Patients with a prior pelvic osteotomy had more revisions due to cup loosening and reported lower PROM scores than patients without earlier osteotomy.Conclusion: 5- and 10-year revision-free implant survival rates of THA for hip dysplasia are 96.4% and 94.9%. Age and prior osteotomies were associated with decreased implant survival rates in patients with hip dysplasia, while fixation method was not. Prior osteotomies were also associated with reduced PROM scores.
- Open Access
- 17 July 2024
- Published by Elsevier in The Journal of Arthroplasty
- Vol. 40 (1) , 208-213.e1
Early Periprosthetic Joint Infections in Total Hip and Knee Arthroplasty: Microorganisms, Mortality, and Implant Survival Using a Combined Dataset From the Dutch Arthroplasty Register and the Dutch National Nosocomial Surveillance Network
- 17 July 2024
- Published by Elsevier in The Journal of Arthroplasty
- Vol. 40 (1) , 208-213.e1
Open AccessEarly Periprosthetic Joint Infections in Total Hip and Knee Arthroplasty: Microorganisms, Mortality, and Implant Survival Using a Combined Dataset From the Dutch Arthroplasty Register and the Dutch National Nosocomial Surveillance Network
- 1 March 2024
- Published by British Editorial Society of Bone & Joint Surgery in The Bone & Joint Journal
- Vol. 106-B (3 Supple A) , 137-142
Survival of cemented short Exeter femoral components in primary total hip arthroplasty
Survival of cemented short Exeter femoral components in primary total hip arthroplasty
- 1 March 2024
- Published by British Editorial Society of Bone & Joint Surgery in The Bone & Joint Journal
- Vol. 106-B (3 Supple A) , 137-142
Survival of cemented short Exeter femoral components in primary total hip arthroplasty
Survival of cemented short Exeter femoral components in primary total hip arthroplasty
- Open Access
- 30 October 2023
- Published by Elsevier in The Journal of Arthroplasty
- Vol. 39 (4) , 1054-1059
Validation of the Incidence of Reported Periprosthetic Joint Infections in Total Hip and Knee Arthroplasty in the Dutch Arthroplasty Register
- 30 October 2023
- Published by Elsevier in The Journal of Arthroplasty
- Vol. 39 (4) , 1054-1059
Open AccessValidation of the Incidence of Reported Periprosthetic Joint Infections in Total Hip and Knee Arthroplasty in the Dutch Arthroplasty Register
- Open Access
- 31 August 2023
- Published by Medical Journals Sweden AB in Acta Orthopaedica
- Vol. 94, 453-459
Short-stem hip arthroplasty in Australia and the Netherlands: a comparison of 12,680 cases between the Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR) and the Dutch Arthroplasty Register (LROI)
Background and purpose: We compared the Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR) and the Dutch Arthroplasty Register (LROI) regarding patient, prosthesis, and procedure characteristics as well as revision rates for uncemented short-stem total hip arthroplasties (THAs).Patients and methods: All THAs with an uncemented short-stemmed femoral component performed between 2009 and 2021 were included from the AOANJRR (n = 9,328) and the LROI (n = 3,352). Kaplan–Meier survival analyses and multivariable Schemper’s weighted Cox regression analyses with data from 2009–2021 and 2015–2021 were performed with overall revision as endpoint.Results: In Australia, the proportion of male patients (51% vs. 40%), patients with ASA III–IV score (30% vs. 3.7%), BMI ≥ 30.0 (39% vs. 19%), and femoral heads of 36 mm (58% vs. 20%) were higher than in the Netherlands. Short-stem THAs in Australia and the Netherlands had comparable 10-year revision rates (3.4%, 95% confidence interval [CI] 2.9–4.0 vs. 4.8%, CI 3.7–6.3). Multivariable Cox regression analyses with data from 2009–2021 showed a higher risk for revision of short-stem THAs performed in the Netherlands (HR 1.8, CI 1.1–2.8), whereas the risk for revision was comparable (HR 0.9, CI 0.5–1.7) when adjusted for more potential confounders using data from 2015–2021.Conclusion: Short-stem THAs in Australia and the Netherlands have similar crude and adjusted revision rates, which are acceptable at 10 years of follow-up.
- 31 August 2023
- Published by Medical Journals Sweden AB in Acta Orthopaedica
- Vol. 94, 453-459
Open AccessShort-stem hip arthroplasty in Australia and the Netherlands: a comparison of 12,680 cases between the Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR) and the Dutch Arthroplasty Register (LROI)
Background and purpose: We compared the Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR) and the Dutch Arthroplasty Register (LROI) regarding patient, prosthesis, and procedure characteristics as well as revision rates for uncemented short-stem total hip arthroplasties (THAs).Patients and methods: All THAs with an uncemented short-stemmed femoral component performed between 2009 and 2021 were included from the AOANJRR (n = 9,328) and the LROI (n = 3,352). Kaplan–Meier survival analyses and multivariable Schemper’s weighted Cox regression analyses with data from 2009–2021 and 2015–2021 were performed with overall revision as endpoint.Results: In Australia, the proportion of male patients (51% vs. 40%), patients with ASA III–IV score (30% vs. 3.7%), BMI ≥ 30.0 (39% vs. 19%), and femoral heads of 36 mm (58% vs. 20%) were higher than in the Netherlands. Short-stem THAs in Australia and the Netherlands had comparable 10-year revision rates (3.4%, 95% confidence interval [CI] 2.9–4.0 vs. 4.8%, CI 3.7–6.3). Multivariable Cox regression analyses with data from 2009–2021 showed a higher risk for revision of short-stem THAs performed in the Netherlands (HR 1.8, CI 1.1–2.8), whereas the risk for revision was comparable (HR 0.9, CI 0.5–1.7) when adjusted for more potential confounders using data from 2015–2021.Conclusion: Short-stem THAs in Australia and the Netherlands have similar crude and adjusted revision rates, which are acceptable at 10 years of follow-up.
- Open Access
- 7 July 2023
- Published by Medical Journals Sweden AB in Acta Orthopaedica
- Vol. 94, 330-335
A comparison of uncemented short versus standard stem length in total hip arthroplasty: results from the Dutch Arthroplasty Register
Background and purpose: We aimed to compare revision rates between uncemented short and standard stems in total hip arthroplasties (THAs) and the corresponding patient-reported outcome measures (PROMs).Patients and methods: We included all short (C.F.P., Fitmore, GTS, Metha, Nanos, Optimys, Pulchra, and Taperloc Microplasty) and standard stems in uncemented THAs registered between 2009 and 2021 in the Dutch Arthroplasty Register. Kaplan–Meier survival and multivariable Cox regression analyses were performed with overall and femoral stem revision as endpoints.Results: Short stems were used in 3,352 and standard stems in 228,917 hips. 10-year overall revision rates (4.8%, 95% confidence interval [CI] 3.7–6.3 vs. 4.5%, CI 4.4–4.6) and femoral stem revision rates (3.0%, CI 2.2–4.2 vs. 2.3%, CI 2.2–2.4) were comparable for short- and standard-stem THAs. Today’s predominant short stems (Fitmore and Optimys) showed short-term revision rates similar to that of standard-stem THAs. Other, less frequently used short stems had higher 10-year overall (6.3%, CI 4.7–8.5) and femoral stem (4.5%, CI 3.1–6.3) revision rates. Multivariable Cox regression also showed a higher risk for overall (HR 1.7, CI 1.0–2.9) and femoral stem revision (HR 2.0, CI 1.1–3.5) using the latter short stems compared with standard stems. An exploratory analysis of PROMs showed no difference.Conclusion: There was no overall difference in revision rates but a tendency toward increased revision of short stems both for the whole THA and for the stem itself. The less frequently used short stems had increased revision risk. No difference in PROMs was shown.
- 7 July 2023
- Published by Medical Journals Sweden AB in Acta Orthopaedica
- Vol. 94, 330-335
Open AccessA comparison of uncemented short versus standard stem length in total hip arthroplasty: results from the Dutch Arthroplasty Register
Background and purpose: We aimed to compare revision rates between uncemented short and standard stems in total hip arthroplasties (THAs) and the corresponding patient-reported outcome measures (PROMs).Patients and methods: We included all short (C.F.P., Fitmore, GTS, Metha, Nanos, Optimys, Pulchra, and Taperloc Microplasty) and standard stems in uncemented THAs registered between 2009 and 2021 in the Dutch Arthroplasty Register. Kaplan–Meier survival and multivariable Cox regression analyses were performed with overall and femoral stem revision as endpoints.Results: Short stems were used in 3,352 and standard stems in 228,917 hips. 10-year overall revision rates (4.8%, 95% confidence interval [CI] 3.7–6.3 vs. 4.5%, CI 4.4–4.6) and femoral stem revision rates (3.0%, CI 2.2–4.2 vs. 2.3%, CI 2.2–2.4) were comparable for short- and standard-stem THAs. Today’s predominant short stems (Fitmore and Optimys) showed short-term revision rates similar to that of standard-stem THAs. Other, less frequently used short stems had higher 10-year overall (6.3%, CI 4.7–8.5) and femoral stem (4.5%, CI 3.1–6.3) revision rates. Multivariable Cox regression also showed a higher risk for overall (HR 1.7, CI 1.0–2.9) and femoral stem revision (HR 2.0, CI 1.1–3.5) using the latter short stems compared with standard stems. An exploratory analysis of PROMs showed no difference.Conclusion: There was no overall difference in revision rates but a tendency toward increased revision of short stems both for the whole THA and for the stem itself. The less frequently used short stems had increased revision risk. No difference in PROMs was shown.